Full-Time

Machine Learning Scientist

Computational Biology, Multiple Levels

Confirmed live in the last 24 hours

Deep Genomics

Deep Genomics

51-200 employees

AI-driven drug discovery for genetic conditions

No salary listed

Mid, Senior

Cambridge, MA, USA + 1 more

More locations: Toronto, ON, Canada

Hybrid work environment; specific in-office days not mentioned.

Category
Applied Machine Learning
Computational Biology
AI & Machine Learning
Biology & Biotech
Required Skills
Tensorflow
Pytorch
Machine Learning
Requirements
  • PhD in Machine Learning, Computational Biology, Bioinformatics, Computer Science, or a related technical field (MSc with significant experience also considered)
  • Extensive experience in designing, training, debugging, and evaluating machine learning models using frameworks like PyTorch, TensorFlow, or JAX
  • Strong foundation in mathematics and statistics, including linear algebra, probability, and optimization
  • Excellent scientific writing and communication skills.
Responsibilities
  • Develop and implement advanced machine learning models for RNA biology, systems biology, and structural biology to solve frontier challenges in drug discovery.
  • Collaborate with cross-functional teams (e.g., ML engineering, target discovery, and experimental biology) to drive research projects that identify novel drug targets and preclinical candidates.
  • Design and execute computational and experimental studies to validate and improve model predictions.
  • Stay informed about the latest advancements in machine learning and computational biology, and apply them to real-world challenges.
  • Share research findings through presentations, publications, and technical discussions.
Desired Qualifications
  • Experience in computational biology, genomics, or drug discovery.
  • Familiarity with RNA biology, structural biology, or systems biology.
  • Proven track record of publishing in top-tier conferences or journals.
  • Experience developing machine learning models for production, particularly in drug design.
  • Proficiency with cloud computing platforms (e.g., AWS, GCP) or distributed computing frameworks.

Deep Genomics focuses on drug development in the biotechnology sector by utilizing artificial intelligence to explore RNA biology and discover potential therapies for genetic conditions. The company's main product, the AI Workbench, is a specialized tool that analyzes data to predict and identify new drug targets. This tool has evolved over time, with versions like AI Workbench 2.0 and the upcoming AI Workbench 3.0, which aim to enhance its capabilities in targeting various genetic mechanisms and diseases. Unlike many competitors, Deep Genomics emphasizes a data-driven approach to drug discovery, allowing it to serve a diverse clientele, including pharmaceutical companies and research institutions. The company's goal is to streamline the drug development process and improve treatment options for patients suffering from genetic disorders.

Company Size

51-200

Company Stage

Series C

Total Funding

$236.8M

Headquarters

Toronto, Canada

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Series B and C funding rounds raised $266 million for R&D.
  • Appointment of Brian O'Callaghan as CEO may accelerate growth and innovation.
  • Industry leaders on the board enhance capabilities in oligonucleotide development.

What critics are saying

  • Emerging genomics startups like Element Biosciences increase market competition.
  • New CEO may disrupt operations or alienate existing partners.
  • BigRNA model may face challenges in adoption within pharmaceutical workflows.

What makes Deep Genomics unique

  • Deep Genomics uses AI to unravel RNA biology for drug development.
  • The AI Workbench identifies novel drug targets and therapeutic candidates.
  • BigRNA model advances RNA disease mechanism discovery and candidate therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

5%

2 year growth

1%
Labiotech
Jan 30th, 2025
Seven Genomics Startups To Look Out For

Newsletter Signup - Under Article / In Page"*" indicates required fields Precision medicine is a kind of treatment strategy that is tailored to individual patients, most of which is dependent on their genetic makeup. Genomics, which deals with the mapping of genomes, is a booming industry that aims to advance precision medicine to address a host of diseases. You may have heard of the big names in the business, like Illumina, Oxford Nanopore Technology, and Thermo Fisher Scientific. But there are a number of genomics startups that have sprouted up in the past decade or so to strengthen their sequencing technologies to aid in disease prevention and treatment. Here are seven genome sequencing startups that are making their mark in the industry.Element BiosciencesFounded in 2017, Element Biosciences shot to fame fairly quickly after the launch of its lab services. Its benchtop sequencing instrument AVITI has a dual flow cell layout and individually addressable lanes and you can perform two parallel runs and operate each side independently. Its alternative model, AVITI LT, is a lower-cost, lower-throughput solution that brings next-generation sequencing (NGS) to more labs.The core components of Element’s sequencing tool include an Avidite base chemistry, which circularizes, copies, and rolls each strand into tightly bound polonies – tiny clusters of identical DNA molecules – without the use of PCR and fluorescent avidites that bind to each polony creating ultrastable complexes. It also employs rolling circle amplification, which is a process that uses a circular DNA template to create long single-stranded DNA molecules to avoid errors such as index hopping – when sequencing reads are incorrectly assigned to the wrong sample in a pool. Its sought-after technology is called LoopSeq, which prepares libraries for long-read sequencing on the short-read Element AVITI System

BioPharmaTrend
Dec 28th, 2023
7 Companies Building Foundation Models in Biology and Chemical Synthesis

For instance, Deep Genomics unveiled BigRNA, a pioneering AI foundation model for uncovering RNA biology and therapeutics.

BioWorld
Sep 28th, 2023
Deep Genomics announces AI foundation model for RNA

Deep Genomics Inc. has introduced its artificial intelligence (AI) foundation model for RNA, BigRNA, which enables discovery of disease mechanisms and candidate therapeutics.

BioSpace
Sep 27th, 2023
Deep Genomics Introduces the Most Advanced AI Foundation Model for RNA Disease Mechanisms and Candidate Therapeutics

Deep Genomics introduces the most advanced AI Foundation model for RNA disease mechanisms and candidate therapeutics.

Business Wire
Sep 15th, 2023
Deep Genomics Announces the Appointment of Brian O'Callaghan as CEO

Deep Genomics announces the appointment of Brian O'Callaghan as CEO.